Overview

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury

Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
To demonstrate the superior effect of ES135 combined with spinal cord repairing surgery, compared to a placebo control with spinal cord repairing surgery, on post-surgery motor function recovery as measured by the changes from baseline of ISNCSCI Motor Scores in subjects
Phase:
Phase 3
Details
Lead Sponsor:
Eusol Biotech Co., Ltd.